The European Commission (EC) has approved Kite’s CAR T-cell therapy, Yescarta, (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.
Kite, a Gilead company, says the US Food and Drug Administration (FDA) has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland.
Gilead’s continued investment in cell therapy manufacturing capabilities, at a time when sales at the nascent business unit are flatlining, was called into question by investors.
The market for cell therapy products is set to expand based on increasing investment from the industry and the implementation of advanced manufacturing technologies.
ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.
